Selective inhibition by somatostatin of cyclic AMP production in rat gastric glands Demonstration of a direct effect on the parietal cell function by Gespach, Christian et al.
Volume 114, number 2 FEBS LE’ITERS June 1980 
SELECTIVE INHIBITION BY SOMATOSTATIN OF CYCLIC AMP PRODUCTION IN RAT 
GASTRIC GLANDS 
~mous~ation of a direct effect on the parietal cell function 
Christian GESPACH, Christophe DUPONT, Dominique BATAILLE and Gabriel ROSSELIN 
Unit& de Recherche de DiabPtologie et d ‘Etudes Radio-Immunoligiques des Hormones Prote’iques (Unite’ INSERM U,SS), 
Centre de Recherches INSERM, Hbpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 7.5571 Paris Cedex 12, France 
Received 24 March 1980 
1. Introduction 
Somatostatin, originally isolated from the hypo- 
thalamus as an inhibitor of growth hormone secretion 
[I], is released from somatostatin~ontaining D cells 
of the stomach [2] and pancreas [2,3] during the 
gastric phase of a meal [4]. In vivo, somatostatin s
reported to inhibit the pepsinogen secretion induced 
by a meal [S] and the gastric acid secretion stimu- 
lated by histamine [6,7]. The presence of specific 
receptors for somatostatin on isolated gastric ells 
from the rat fundus [8] strongly suggests hat soma- 
tostatin exerts a direct effect on these exocrine secre- 
tory processes: We have shown that secretin which 
stimulates pepsinogen [9] and mucous [lo] secre- 
tions is highly potent in stimulating cyclic AMP pro- 
duction in gastric glands isolated from the rat fundus 
and antrum, while histamine is only effective on the 
acid-secreting fundic preparation [ 1 l]. Here we 
have examined therefore the ability of somatostat~ 
to inhibit both secretin and histamine-induced cyclic 
AMP formation in our system. The effect of cimetidine, 
a specific Hz-receptor antagonist [ 121 was also inves- 
tigated since it has been shown that histamine stimu- 
lates gastric acid secretion by interacting with an 
Hz-receptor cyclic AMP system [131 present in 
parietal cells ]14]. 
Our data demonstrate hat somatostatin (1 O-‘- 
low6 M) reduces considerably the effect of histamine 
on the cyclic AMP production in a non-competitive 
way, while cimetidine (1 O-*-l O4 M) inhibits com- 
petitively the histamine stimulation. In contrast, no 
effect of somatostatin was found on the cyclic AMP 
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system highly sensitive to secretin in both fundic and 
antral regions of the rat stomach. 
2. Materials and methods 
2.1. Experirnen fal conditions 
Gastric glands were isolated from the stomach of 
male Wistar ats (200-250 g) using EDTA [ 151 as in 
[ 111. In a standard assay, cyclic AMP production was 
measured ingastric glands (5- 15 pg cell DNA/ml) 
incubated at 20°C in 0.5 ml KRP (pH 7.5), contain- 
ing 2% BSA and 0.5 mM 3-isobu~l-l-methy~an~~e 
(iBuMeXan) as a phosphodiesterase inhibitor. The 
reaction was started by the addition of 100 ~1 agents 
after 10 mm preincubation of the other reaction 
constituents. The incubation was stopped after 60 
min by the addition of 50 ~1 11 N HC104. Cyclic 
AMP was determined using the radio~muno~say 
technique in [ 161. DNA and protein contents were 
measured in homogenates of gastric glands as in 
[ 171 and [ 181, respectively. Data were expressed in
pmol cyclic AMP/pg cell DNA. The suspension of
gastric glands contained 13.5 + 1 .l pg DNA or 
4.4 ?; 1.6 fig protein per lo6 cells. In the presence 
of 0.5 mM iBuMeXan, basal cyclic AMP production 
averaged 2.64 + 0.1 and 3.8 * 0.2 pmol cyclic AMP 
per lo6 cellsat 2O*C and 37*C,respectively @<O.OOl, 
n = 6). Those values are consistent with those obtained 
in mucosal preparations from the canine ] 191 and 
guinea pig [20] fundus. 
247 
Volume 114, number 2 FEBS LETTERS 
2.2. Statistical analysis 
Regression lines were calculated by the least 
squares method. The significance of the differences 
between paired values were calculated by the 
Student’s t-test. 
2.3. Chemicals 
Synthetic porcine secretin (lot S19) was gener- 
ously supplied by Professor E. Wiinsch (Abteilung 
fur Peptidchemie, Martinsried) and highly purified 
natural VIP was a generous gift from Professor 
V. Mutt (GIH Lab., Stockholm) through Gastroin- 
testinal Hormones Resources (NIHMD). Cimetidine 
(SKF 92334, lot 8R 118) was kindly supplied by 
Mrs D. M. Francis (Smith, Kline and French Labs., 
Welwyn Garden City, Hertfordshire). The synthetic 
cyclic somatostatin (lot E 0535) was purchased from 
Beckman (Switzerland). All other chemicals were 
of analytical grade. 
3. Results 
3 .l . Effect of somatostatin on basal and secretin- 
induced cyclic AMP formation in rat gastric 
glands 
The effect of somatostatin was studied at concen- 
trations of secretin producing maximal and half- 
June 1980 
maximal stimulation of cyclic AMP production [ 1 I]. 
Somatostatin 10” M had no significant effect on 
basal and secretin-stimulated cyclic AMP production 
in rat gastric glands (table 1). In the same conditions, 
somatostatin was also unable to cause a detectable 
effect on the VIP-induced cyclic AMP formation 
which was mediated by the secretin-sensitive cyclic 
AMP system [ 1 l] in gastric glands isolated from 
either the rat fundus or antrum (data not shown). 
3.2. Effect of somatostatin on histamine-induced 
cyclic AMP formation in rat gastric glands 
The optimal conditions for the histamine stimula- 
tion are shown in tig.1. The addition of 0.5 mM 
iBuMeXan, as a phosphodiesterase inhibitor, caused 
an -2.3-fold increase over basal cyclic AMP produc- 
tion (0.196 f 0.007 vs 0.083 f 0.015 pmol cyclic 
AMP/pg cell DNA) and a maximal potentiation of 
the effect of histamine (fig.1 A). Maximal and half- 
maximal effects were obtained by incubating fundic 
glands for 1 h at 20°C with 5 . 10e3 and 5 . 10” M 
histamine, respectively (tig.lB). In accordance with 
[21], histamine had no effect on cyclic AMP pro- 
duction in gastric glands isolated from the antrum 
(table 1). In gastric fundus, the addition of soma- 
tostatin 10d M produced a 64 and 61% inhibition 
of the effect produced by 5 . lo4 and 5 . 10e3 M 
histamine, respectively (table 1). 
Table 1 
Effect of lo-’ M somatostatin on basal and cyclic AMP production stimulated 
by secretin (A) or histamine (B) in rat gastric glands 
Additive Cyclic AMP (pmol/g DNA) 
Fundus Antrum 
A. Control 0.184 f 0.009 (8) 0.080 i 0.006 (9) 
Somatostatin 0.165 + 0.010 0.083 f 0.013 
Secretin 10eg M 2.36 f 0.070b (13) 3.52 i 0.287b (9) 
Secretin + somatostatin 2.43 f 0.108 4.13 f 0.188 
Secretin lo-’ M 5.49 * 0.307b (8) 8.18 i 0.397b (6) 
Secretin + somatostatin 5.55 f 0.479 7.26 f 0.461 
B. Histamine 5 . 10m4 M 2.59 I 0.092b (6) 0.065 + 0.028 (5) 
Histamine + somatostatin 0.937 f 0.087a 
Histamine 5 . 10-a M 5.69 *0.171b (6) 0.103 + 0.006 (5) 
Histamine + somatostatin 2.26 f 0.343a 
a,b p < 0.05 or better from controlb or from corresponding value in absence of 
somatostatina by paired Student’s f-test 
Gastric glands were incubated under the conditions in section 2. The values given 
are the means + SE for the no. determinations hown in parentheses 
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Fig.1. Cyclic AMP production in rat fundic glands: (A) effect 
of iBuMeXan as a phosph~iesterase inhibitor in the absence 
(+) or in presence of 10W3 M histamine (a); (B) effect of 
various concentrations of histamine (a), in the presence of 
0.5 mM iBuMeXan. Mean values f SEM of 3 separate xpt 
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Fig.2. Time course of cyclic AMP production in rat fundic 
glands incubated at 20 or 37°C in the absence of effector 
(4) and in presence of lo-’ M histamine (a) or histamine 
plus 10e6 M ~matosta~ (0). Values are mean f SEM of 
triplicates. A second experiment gave similar results. 
3.3. Effect of time and temperature on the inhibitory 
effect of somatostatin on cyclic AMP production 
induced by histamine in rat fundic glands 
As shown in fig.2, histamine 1 0W3 M increased the 
production of cyclic AMP within 1 min at 20°C; the 
effect was maximal (I)-fold increase over control) 
at 60 min and cyclic AMP levels became constant for 
the 90 min incubation. When somatostatin lo6 M 
(a dose that is maximally effective in inhibiting cyclic 
AMP production induced by histamine, vide infra) 
was added to histamine, cyclic AMP levels were signif- 
icantly reduced for the entire experimental period 
(p < 0.001). At 37*C the initial veiocity of cyclic 
AMP production induced by histamine was higher, 
but the extent of the maximal stimulation (6.fold 
increase over control) was lower than that observed at 
20°C (fig.2). At this physiological temperature, soma- 
tostatin also reduced cyclic AMP accumulation during 
the 60 min incubation with histamine. The addition 
of somatostatin does not alter the time course of 
the increase in cyclic AMP caused by histamine, since 
cyclic AMP became maximal and constant‘in the 
presence or in the absence of somatostatin by 60 min 
and 30 min at 20 and 37*C, respectively (fig.2). 
3.4. Effect of famous condensations of somatostati~ 
and histamine on cyclic AMP production in rat 
fundic glands 
Since histamine 1 0W3 M produced a maximal 
increase in cyclic AMP production after a 60 min 
incubation at 2O”C, the characteristics of the inhibi- 
tory effect of somatostatin were studied under these 
experimental conditions. Cyclic AMP fo~ation 
induced by 1 O4 and 1 0m3 M histamine was decreased 
by IO-’ M somatostatin; maximal inhibition was 
obtained with lo-’ and 10” M somatostatin, respec- 
tively (fig.3A). At this concentration of inhibitor, 
Fig.3. (A) Effect of various concentrations of somatostatin 
on cyclic AMP production induced by 10s4 M (A) or 10-a M 
(a) histamine in rat fundic glands. Mean values f SEM of 2 
separate xpt performed in triplicate. (B) Lineweaver-Burk 
analysis of the cyclic AMP production induced by 10e4 to 
5 . lo-’ M histamine (8) and by histamine plus IO-’ M 
(0) or to IO-’ M (A) somatostatin. Equations of the regres- 
sion lines and correlation coefficients were as follows: 
y = 0.065x + 203, r = 0.981 (p < O.c)Ol) for histamine alone; 
y = 0.081x + 0.305, r = 0,931 @ < 0.001) andy = 0.138.x + 
0.433, r = 0.937 @ < 0.001) for histamine plus IO-* and 
lo-” M somatostatin, respectively. 
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cyclic AMP production induced by histamine was 
again significantly elevated compared to control 
(p < 0.001). Half-maximal inhibition of the increase 
in cyclic AMP (//)so) caused by 10 -4 and 10 -3 M 
histamine occurred with 10 -~ M somatostatin. As
shown in fig.3B, the Lineweaver-Burk analysis [22] 
of our data shows that somatostatin i hibits hista- 
mine-induced cyclic AMP production by changing the 
maximal response while the apparent half-maximal 
stimulation (3 .10  -4 M histamine) was not changed 
in the presence of the inhibitor: this is typical of a 
non-competitive type of inhibition. 
3.5. Effect of cimetidine on basal, secretin and 
histamine4nduced yclic AMP formation in 
rat fundic glands 
We found that cimetidine had no effect on basal or 
secretin-stimulated cyclic AMP production in gastric 
glands isolated from the rat fundus or antrum (data 
not shown). The inhibitory effect of cimetidine on 
cyclic AMP formation induced by histamine 10-4 or 
10 -a M could be detected at 10 "~ M cimetidine, was 
half.maximal t 3 .10  -7 and 8 .10  -7 M and was 
maximal at 10 -s and 10-4 M cimetidine, respec- 
tively (fig.4A). At these concentrations of inhibitor, 
the stimulatory effect produced by histamine (10 -4 
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Fig.4. (A) Effect of various concentrations of cimetidine on 
cyclic AMP production induced by 10 -~ M (A)or 10 "3 M (o) 
histamine in rat fundic glands. Mean values ± SEM of 2 sepa- 
rate expt performed intriplicate. (B) Lineweaver-Burk analy- 
sis of the cyclic AMP production i duced by 10 -4 to 10 "~ M 
histamine (o) and by histamine plus 10 -7 M (o) or 10 -~ M 
(zx) cimetidine. Equations of the regression li es and correla- 
tion coefficients were as follows: y --- 0.056x + 0.251, 
r = 0.898 (p < 0.001) for histamine alone; y = 0.257x + 0.227, 
r = 0.984 (p < 0.001) andy = 0.826x + 0.305, r --- 0.992 
(p < 0.001) for histamine plus 10 -7 and 10 -~ M cimetidine, 
respectively. 
the Lineweaver-Burk transformation f our data in 
fig.4B indicates that cimetidine inhibits histamine- 
induced cyclic AMP production by changing the 
apparent half-maximal stimulation with no modifica- 
tion of the maximal response, i.e., in a competitive 
way. Thus, our results with cimetidine characterized 
the action of histamine on gastric glands as an H2 
receptor activation implicated in gastric acid secretion 
since this H2 receptor antagonist could inhibit both 
histamine-induced cyclic AMP formation [23] and 
gastric acid secretion in man [24]. 
4. Discussion 
These data suggest that the inhibitory effect of 
somatostatin on histamine-stimulated cyclic AMP 
production in rat gastric glands accounts for the 
direct inhibition by somatostatin on the release of 
hydrochloric acid by the stomach. In vivo and in 
vitro, somatostatin i hibits histamine-induced gastric 
acid secretion in a variety of species [6,7,25] by a 
non-competitive mechanism [7,25], similarly to the 
non-competitive inhibition of cyclic AMP production 
by somatostatin observed in our system. This mecha- 
nism excludes that somatostatin might interact 
directly with the H2 receptors for histamine [26] 
and suggests that the somatostatin binding sites 
shown in parietal cells [8] are biologically functional 
in the rat fundus. Indeed, the app. K d (4.5.10 -9 M) 
of these sites is consistent with the IDso (10 -s M) of 
the somatostatin i hibition in rat gastric glands 
(section 3). Furthermore, the elevation of soma- 
tostatin in venous effluents to "~10 -9 M in response 
to nutrients or HC1 administration i  dogs [4,27] 
and rats [28] compares well with the potency of 
somatostatin on the histamine-sensitive cyclic AMP 
system here. The concentration of somatostatin i  
contact with parietal cells is also dependent on the 
paracrine function [29] of the gastric D cells that 
secretes somatostatin [30,31 ], in the vicinity of 
parietal cells [32,33]. 
On the other hand, we found that somatostatin 
had no significant effect on the cyclic AMP system 
highly sensitive to secretin in gastric glands isolated 
from the rat fundus and antrum. The stimulation 
of cyclic AMP production by secretin was localized 
in non-parietal cells in rat [ 11 ] and dog stomach 
[19] and correlated with the distribution ofpepsin- 
ogen in isolated canine mucosal cells [19]. Thus, 
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although somatostatin hibits the pepsinogen secre- 
tion in man [ 51 and dog [34], it did not seem effective 
in inhibiting the secretin-sensitive cyclic AMP system 
in the rat gastric mucosa. The biological significance 
of the somatostatin binding sites shown in chief 
and/or mucous cells of the rat fundus [8] remains 
unknown, 
In conclusion, it appears that somatostatin scapa- 
ble of a direct inhibition of the histamine-sensitive 
cyclic AMP system involved in the gastric acid secre- 
tion but fail to inhibit the secretin-sensitive cyclic 
AMP system in pepsinogen- and/or mucous-secreting 
cells. This does not exclude that somatostat~ can 
inhibit gastric acid secretion indirectly by lowering 
the gastrin release as shown in vivo [35,36] and in 
vitro [37]. Our results may clarify the mode of action 
of regulatory peptides on gastric secretion: To date, 
the absence of any evidence for a direct effect of 
secre tin or VIP on parietal cells is surprising in regard 
to their inhibition on gastric. acid secretion in vivo 
[38,39]. Therefore, the stimulation of gastric and 
pancreatic somatostatin release by those peptides 
[40--42], together with the demonstration of the 
direct regulation by somatostatin of the histamine-Hz 
receptor activation in rat gastric glands, could be an 
important scheme by which peptides no~ally 
modulate gastric acid secretion. 
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